Lybrate is India’s first and largest online doctor consultation platform. By seamlessly connecting doctors and patients through our health app and making them communicate using mobile phones, we make healthcare more accessible. Join us on our mission to change the way healthcare is delivered in India.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

EMPATICA RECEIVES NEW FDA CLEARANCE FOR ITS HEALTH MONITORING PLATFORM AND ANNOUNCES SERIES B FINANCING

Empatica | November 23, 2022

news image

Empatica, a digital health and AI company developing medical-grade wearables and algorithms for health monitoring and diagnostics, today announced the clearance of its Empatica Health Monitoring Platform by the U.S. Food and Drug Administration. The Empatica Health Monitoring Platform is a full-stack remote health monitoring and data collection solution for research and healthcare professionals, built on data collected by Empatica's medical-grade, CE-certified EmbracePlus wear...

Read More

MEDICAL

THERMO FISHER SCIENTIFIC OPENS BIOPROCESSING MANUFACTURING SITE IN OGDEN, UTAH

Thermo Fisher Scientific | April 21, 2022

news image

Thermo Fisher Scientific today celebrated the opening of its new single-use technology manufacturing site in Ogden, Utah. The state-of-the-art facility creates additional capacity to produce the high-quality technology and materials needed for the development of new vaccines and breakthrough therapies. The $44 million facility is part of Thermo Fisher’s $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity ...

Read More

INDUSTRIAL IMPACT

QIAGEN AND NEURON23 PARTNER TO DEVELOP NEXT-GENERATION SEQUENCING COMPANION DIAGNOSTIC FOR NOVEL PARKINSON’S DISEASE DRUG

QIAGEN and Neuron23™ | September 15, 2022

news image

QIAGEN and Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase inhibitor for Parkinson’s disease. Under the new Master Collaboration Agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of bi...

Read More

INDUSTRIAL IMPACT

BICYCLE THERAPEUTICS ANNOUNCES EXPANSION OF GENENTECH IMMUNO-ONCOLOGY COLLABORATION

Bicycle Therapeutics | October 26, 2021

news image

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Bicycle and Genentech are collabora...

Read More
news image

INDUSTRIAL IMPACT

EMPATICA RECEIVES NEW FDA CLEARANCE FOR ITS HEALTH MONITORING PLATFORM AND ANNOUNCES SERIES B FINANCING

Empatica | November 23, 2022

Empatica, a digital health and AI company developing medical-grade wearables and algorithms for health monitoring and diagnostics, today announced the clearance of its Empatica Health Monitoring Platform by the U.S. Food and Drug Administration. The Empatica Health Monitoring Platform is a full-stack remote health monitoring and data collection solution for research and healthcare professionals, built on data collected by Empatica's medical-grade, CE-certified EmbracePlus wear...

Read More
news image

MEDICAL

THERMO FISHER SCIENTIFIC OPENS BIOPROCESSING MANUFACTURING SITE IN OGDEN, UTAH

Thermo Fisher Scientific | April 21, 2022

Thermo Fisher Scientific today celebrated the opening of its new single-use technology manufacturing site in Ogden, Utah. The state-of-the-art facility creates additional capacity to produce the high-quality technology and materials needed for the development of new vaccines and breakthrough therapies. The $44 million facility is part of Thermo Fisher’s $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity ...

Read More
news image

INDUSTRIAL IMPACT

QIAGEN AND NEURON23 PARTNER TO DEVELOP NEXT-GENERATION SEQUENCING COMPANION DIAGNOSTIC FOR NOVEL PARKINSON’S DISEASE DRUG

QIAGEN and Neuron23™ | September 15, 2022

QIAGEN and Neuron23 Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, announced the signing of an agreement to develop a companion diagnostic for Neuron23’s brain penetrant leucine-rich repeat kinase inhibitor for Parkinson’s disease. Under the new Master Collaboration Agreement, QIAGEN will develop and validate a clinical trial assay that will detect a combination of bi...

Read More
news image

INDUSTRIAL IMPACT

BICYCLE THERAPEUTICS ANNOUNCES EXPANSION OF GENENTECH IMMUNO-ONCOLOGY COLLABORATION

Bicycle Therapeutics | October 26, 2021

Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised an option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies. Bicycle and Genentech are collabora...

Read More